News

head uk2

Publications in 2012

Find an overview of scientific publications dealing with chitin and chitosan in 2012.

Publications in March 2012

Overall 131 articles about chitosan and chitosan derivatives were published in March 2012.

As in the previous month, China is the country with the most publications with overall 35 articles, followed by the USA (14 articles), India (9 articles) and Taiwan (8 articles).

 

drug delivery, nanoparticles, nanocarriers

Read more Publications in March 2012

Chitin - bio-raw material for NeuNAc production

In February 2012 the Technical University (TU) of Vienna filed a patent for a new production method of the popular pharmaceutical raw material N-acetylneuraminic acid (NeuNAc). Molds were used as “chemical factories” and were combined with the biological raw material chitin to obtain the desired final product.

chitosan, chitin, NeuNAc, antiviral drugs

Read more Chitin - bio-raw material for NeuNAc production

Congress and fairs

Meet us in person 2023:

  • EASO Winterschool 2023, Wittenberg, Germany, 15.02.-18.02.2023
  • EUCHIS 2023, Siglufjörður, Iceland, 11.-14.09.2023
  • EPNOE 2023, Graz, Austria, 18.09.-22.09.2023
  • Asia Pacific Chitin and Chitosan Symposium 2023, Juju, South-Korea, 31.10.-03.11.2023
  • Bioeconomy Innovation Day, Brussels, Belgium, 16.11.2023

To arrange an appointment please contact Katja Richter via sales(at)medical-chitosan.com

Contact

  • Heppe Medical Chitosan GmbH
    Heinrich-Damerow-Strasse 1
    06120 Halle (Saale)
    Germany
  • Tel.: +49 (0) 345 27 996 300
    Fax: +49 (0) 345 27 996 378
  • This email address is being protected from spambots. You need JavaScript enabled to view it.
Contact | GTC / Terms of Use | Legal info | Copyright © 2024 Heppe Medical Chitosan GmbH | Privacy notice

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.